Abstract | OBJECTIVE: METHODS: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index. RESULTS: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups. CONCLUSIONS:
|
Authors | Rebecca S Nelken, Begüm Z Ozel, Ava R Leegant, Juan C Felix, Daniel R Mishell Jr |
Journal | Menopause (New York, N.Y.)
(Menopause)
Vol. 18
Issue 9
Pg. 962-6
(Sep 2011)
ISSN: 1530-0374 [Electronic] United States |
PMID | 21532512
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Mandelic Acids
- Muscarinic Antagonists
- Estradiol
- oxybutynin
|
Topics |
- Aged
- Contraceptive Devices, Female
- Estradiol
(therapeutic use)
- Female
- Humans
- Mandelic Acids
(therapeutic use)
- Middle Aged
- Muscarinic Antagonists
(therapeutic use)
- Quality of Life
- Treatment Outcome
- Urinary Bladder, Overactive
(drug therapy)
- Urinary Incontinence
(drug therapy)
|